Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enwei Pharmaceutical CoSZSE:301331 -0.86%76 Pretax Margin % is 7.92% as of Mar. 2026, which is 52% below its 10-year median of 16.43. GuruFocus rates SZSE:301331 with a GF Score™ of 76/100 and a GF Value™ of ¥28.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 958 Drug Manufacturers companies, Enwei Pharmaceutical Co ranks worse than 51.36% on this metric.
The historical rank and industry rank for Enwei Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
SZSE:301331'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.75 Med: 16.43 Max: 19.63
Current: 6.83
SZSE:301331's Pretax Margin % is ranked worse than 51.36% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.455
vs SZSE:301331: 6.83
Enwei Pharmaceutical Co (SZSE:301331) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Enwei Pharmaceutical Co Pretax Margin % Related Terms
Enwei Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enwei Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enwei Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enwei Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Enwei Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enwei Pharmaceutical Co (SZSE:301331) has a Pretax Margin % of 7.92% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enwei Pharmaceutical Co and its competitors. This is 52% below median its historical median of 16.43. Over the past decade, Enwei Pharmaceutical Co's Pretax Margin % has ranged from 5.75 to 19.63. According to the industry distribution chart, Enwei Pharmaceutical Co ranks #492 out of 958 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Enwei Pharmaceutical Co's Pretax Margin % too high?
Enwei Pharmaceutical Co's current Pretax Margin % of 7.92% is 52% below median its 10-year median of 16.43. Over the past 10 years, this metric has ranged from a low of 5.75 to a high of 19.63. The Drug Manufacturers industry median Pretax Margin % is 7.46. Enwei Pharmaceutical Co's value of 7.92% is 6.2% above this industry median. Based on the distribution chart, Enwei Pharmaceutical Co ranks #492 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Enwei Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enwei Pharmaceutical Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enwei Pharmaceutical Co ranks #492 out of 958 companies for Pretax Margin %. This places Enwei Pharmaceutical Co in the lower half of its industry. The industry median Pretax Margin % is 7.46. Enwei Pharmaceutical Co's value of 7.92% is 6.2% above this benchmark. Historically, Enwei Pharmaceutical Co's own Pretax Margin % has ranged from 5.75 to 19.63 over the past decade. While the company's 10-year median is 16.43 vs. the industry median of 7.46, Enwei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.46, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enwei Pharmaceutical Co's current Pretax Margin % of 7.92% is 6.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enwei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enwei Pharmaceutical Co's current Pretax Margin % is 7.92%, which is 52% below median its own 10-year median of 16.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enwei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co (SZSE:301331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.16, compared to a current price of ¥21.84 — trading 22.4% below its estimated fair value. The current Pretax Margin % is 7.92%, which is 52% below median its 10-year median of 16.43 and 6.2% above the Drug Manufacturers industry median of 7.46. Enwei Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Enwei Pharmaceutical Co (SZSE:301331), the current Pretax Margin % is 7.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enwei Pharmaceutical Co (SZSE:301331) Overvalued in 2026?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥21.84 is trading 22.4% below its estimated GF Value™ of ¥28.16.
GuruFocus considers Enwei Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SZSE:301331:
Pretax Margin %: 7.92% (52% below median its 10-year median of 16.43)
GF Value™: ¥28.16 vs. price of ¥21.84 (22.4% below fair value)
Industry Position: 6.2% above the Drug Manufacturers median (#492 of 958)
No single metric tells the full story. See the SZSE:301331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
76GF Score
Get the complete analysis for SZSE:301331
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301331 has been successfully added to your 
